54 related articles for article (PubMed ID: 31599770)
1. Novel molecular targets for the treatment of lung cancer.
Rosell R; Karachaliou N; Arrieta O
Curr Opin Oncol; 2020 Jan; 32(1):37-43. PubMed ID: 31599770
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
Bodor JN; Boumber Y; Borghaei H
Cancer; 2020 Jan; 126(2):260-270. PubMed ID: 31691957
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Chen R; Zhao WQ; Fang C; Yang X; Ji M
J Cancer; 2020; 11(11):3349-3356. PubMed ID: 32231741
[TBL] [Abstract][Full Text] [Related]
4. Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Santarpia M; Aguilar A; Chaib I; Cardona AF; Fancelli S; Laguia F; Bracht JWP; Cao P; Molina-Vila MA; Karachaliou N; Rosell R
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516941
[TBL] [Abstract][Full Text] [Related]
5. New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A; Lopes AR; McCusker MG; Garrigues SG; Ricciardi GR; Arensmeyer KE; Scilla KA; Mehra R; Rolfo C
Curr Oncol Rep; 2020 Apr; 22(5):48. PubMed ID: 32296961
[TBL] [Abstract][Full Text] [Related]
6. Lung Cancer Pathology: Current Concepts.
Travis WD
Clin Chest Med; 2020 Mar; 41(1):67-85. PubMed ID: 32008630
[TBL] [Abstract][Full Text] [Related]
7. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
Imyanitov EN; Iyevleva AG; Levchenko EV
Crit Rev Oncol Hematol; 2021 Jan; 157():103194. PubMed ID: 33316418
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
9. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Yuan M; Huang LL; Chen JH; Wu J; Xu Q
Signal Transduct Target Ther; 2019; 4():61. PubMed ID: 31871778
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers in early stage lung cancer.
Rodríguez M; Ajona D; Seijo LM; Sanz J; Valencia K; Corral J; Mesa-Guzmán M; Pío R; Calvo A; Lozano MD; Zulueta JJ; Montuenga LM
Transl Lung Cancer Res; 2021 Feb; 10(2):1165-1185. PubMed ID: 33718054
[TBL] [Abstract][Full Text] [Related]
11. Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.
Li XJ; Li QL; Ju LG; Zhao C; Zhao LS; Du JW; Wang Y; Zheng L; Song BL; Li LY; Li L; Wu M
Hepatology; 2021 May; 73(5):1797-1815. PubMed ID: 33058300
[TBL] [Abstract][Full Text] [Related]
12. A BRAF new world.
Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A
Crit Rev Oncol Hematol; 2020 Aug; 152():103008. PubMed ID: 32485528
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer.
Ruiz-Cordero R; Devine WP
Surg Pathol Clin; 2020 Mar; 13(1):17-33. PubMed ID: 32005431
[TBL] [Abstract][Full Text] [Related]
14. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
16. Advancement of regulating cellular signaling pathways in NSCLC target therapy via nanodrug.
Li W; Li M; Huang Q; He X; Shen C; Hou X; Xue F; Deng Z; Luo Y
Front Chem; 2023; 11():1251986. PubMed ID: 37744063
[TBL] [Abstract][Full Text] [Related]
17. Tectoridin and PLK1 inhibitor synergistically promote the apoptosis of lung adenocarcinoma cells: Bioinformatic analysis of TCGA and TCMSP.
Wang M; Zhao F; Li Z; Li X; Dong L
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2417-2426. PubMed ID: 37014402
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis in lung cancer: a novel pathway regulating cell death and a promising target for drug therapy.
Xing N; Du Q; Guo S; Xiang G; Zhang Y; Meng X; Xiang L; Wang S
Cell Death Discov; 2023 Apr; 9(1):110. PubMed ID: 37005430
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive bioinformatics analysis to identify a novel cuproptosis-related prognostic signature and its ceRNA regulatory axis and candidate traditional Chinese medicine active ingredients in lung adenocarcinoma.
Wang S; Xing N; Meng X; Xiang L; Zhang Y
Front Pharmacol; 2022; 13():971867. PubMed ID: 36110528
[TBL] [Abstract][Full Text] [Related]
20. Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review.
Md S; Alhakamy NA; Karim S; Gabr GA; Iqubal MK; Murshid SSA
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
